Is There Enough Evidence to Avoid Remdesivir Use in Patients with Severe Renal Impairment? A Review of the Pharmacological and Clinical Literature
Although patients with severe renal impairment (SRI) typically experience more critical symptoms once infected with novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus-2, this population has often been excluded from randomized controlled trials (RCT) for Coronavirus disease-2019 (COVID-...
Saved in:
| Main Authors: | Suresh J. ANTONY, Emily L. HEYDEMANN, Katrina M. BROWN |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2021-12-01
|
| Series: | Mediterranean Journal of Infection, Microbes and Antimicrobials |
| Subjects: | |
| Online Access: | http://mjima.org/abstract.php?id=231 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety evaluation of remdesivir administration in patients with severe renal impairment and coronavirus disease: a systematic review and meta-analysis
by: Takumi Umemura, et al.
Published: (2025-06-01) -
Pharmacokinetic simulations for remdesivir and its metabolites in healthy subjects and patients with renal impairment
by: Shengjie Zhang, et al.
Published: (2025-03-01) -
Outcome of COVID-19 and tolerance of Remdesivir in patients with renal failure: a single center experience from Pakistan
by: Zaheer Udin Babar, et al.
Published: (2023-06-01) -
Association of secondary hyperparathyroidism with mild cognitive impairment in end-stage renal disease patients
by: Zhang Qian, et al.
Published: (2021-01-01) -
Integrative approaches to depression in end-stage renal disease: insights into mechanisms, impacts, and pharmacological strategies
by: Cheng Yuan, et al.
Published: (2025-04-01)